Summary 1
Trophoblasts are the principal cell type of the placenta. The use of human trophoblast stem cells 2 (hTSCs) as a model for studies of early placental development is hampered by limited genetic 3 diversity of existing hTSC lines, and constraints on using human fetal tissue or embryos needed 4 to generate additional cell lines. Here we report the derivation of two distinct stem cells of the 5 trophectoderm lineage from human pluripotent stem cells. The first is a CDX2-stem cell equiva-6 lent to primary hTSCsthey both exhibit identical expression of key markers, are maintained in 7 culture and differentiate under similar conditions, and share high transcriptome similarity. The 8 second is a CDX2+ putative human trophectoderm stem cell (hTESC) with distinct cell culture 9 requirements and differences in gene expression and differentiation relative to hTSCs. Derivation 10 of hTSCs and hTESCs from pluripotent stem cells significantly enables construction of models for 11 normal and pathological placental development.
Introduction 13
Specification of the trophectoderm and the inner cell mass (ICM) is the first differentiation 14 event during human embryonic development. The trophectoderm mediates blastocyst implanta-15 tion in the uterus and is the precursor to all trophoblast cells in the placenta. Upon embryo im-16 plantation, the trophectoderm forms the cytotrophoblast (CTB), a putative stem cell that can dif-17 ferentiate to form the two major cell types in the placentathe extravillous trophoblast (EVT) and 18 the syncytiotrophoblast (STB) (Benirschke et al., 2012; Bischof and Irminger-Finger, 2005) . The 19
EVTs are involved in remodeling of uterine arteries, which is critical to ensure adequate perfusion 20 of the placenta with maternal blood, whereas the multinucleated STB mediates the nutrient and 21 gas exchange at the maternal-fetal interface (Moser et al., 2011; Yabe et al., 2016) . Abnormalities 22 in trophoblast development are associated with pregnancy-related pathologies such as miscar-23 riage, preeclampsia and placenta accreta. Yet, despite its relevance to maternal and fetal health, 24 constraints on research with human embryos and early fetal tissue impede mechanistic insight 25 into early trophoblast development. 26
Trophoblast stem cells derived from first trimester human placental samples and blasto-27 cyst-stage embryos have emerged as an attractive in vitro model system for early human troph-28 oblast (Okae et al., 2018) . However, restricted accessibility of embryos and placental samples 29 from early gestation and low genetic diversity of existing cell lines limit the use of this model. In 30 contrast, pluripotent stem cells are a more accessible source for generation of in vitro models of 31 human trophoblast. More importantly, unlike early gestation primary samples where the projected 32 pregnancy outcome is uncertain, human induced pluripotent stem cells (hiPSCs) can potentially 33 provide models of validated normal and pathological trophoblast development (Sheridan et al., 34 2019) . However, whether bona fide trophoblast can be obtained from pluripotent stem cells has 35 been a subject of intense debate (Roberts et al., 2014) . A rigorous head-to-head comparison 36 between trophoblast derived from pluripotent stem cells and their in vivo counterparts has proven 37 difficult due to multiple reasons. Previous studies have used varying experimental protocols 38 (Roberts et al., 2018) , a self-renewing trophoblast stem cell population has not been derived from 39 human pluripotent stem cells, and both primary placental samples and cultures of terminally dif-40 ferentiated trophoblast obtained from pluripotent stem cells exhibit heterogeneity and contain 41 many cell types. 42
In this study, we report the derivation and maintenance of two distinct trophectoderm lin-43 eage stem cells from human embryonic stem cells (hESCs) and hiPSCs in chemically defined 44 culture conditions. The first is a CDX2-human trophoblast stem cell (hTSC) that is comparable to 45 primary hTSCs derived from early gestation placental samples. The second is a more primitive 46 CDX2+ cell type that is a putative human trophectoderm stem cell (hTESC) (Knöfler et al., 2019) . 47
Critically, the isolation of self-renewing stem cell populations allowed a direct comparison of pri-48 mary hTSCs with pluripotent stem cell derived hTSCs; genome wide transcriptomic analysis and 49 functional differentiation assays establish their equivalence. The routine derivation of hTSCs and 50 hTESCs from pluripotent stem cells will provide powerful tools for mechanistic studies on normal 51 and pathological early trophoblast development. 52
Results 53
A chemically defined medium containing S1P enables differentiation of hESCs to CTB. 54
Media formulations in previous studies on trophoblast differentiation of hESCs included 55 components such as knockout serum replacement (KSR) or bovine serum albumin (BSA) that act 56 as carriers for lipids. Pertinently, albumin-associated lipids have been implicated in activation of 57 G-protein coupled receptor (GPCR)-mediated signaling (Mendelson et al., 2014; Yu et al., 2012) . 58
For instance, the phospholipid sphingosine-1 phosphate (S1P) present in KSR can activate YAP 59 signaling; YAP plays a critical role in specification of the trophectoderm in mouse (Knott and Paul, 60 2014; Nishioka et al., 2008; Yagi et al., 2007) . We investigated the use of S1P in the context of 61 trophoblast differentiation of hESCs under chemically defined culture conditions, by modifying our 62 previous protocol that utilized KSR (Sarkar et al., 2015 . H1 and H9 hESCs cultured in E8 63 medium were differentiated for 6 days in E7 medium (E8 without TGF1) supplemented with S1P, 64 by treatment with BMP4 and the activin/nodal inhibitor SB431542 (Figure 1A) . Under these con-65 ditions, we observed upregulation of the CTB markers CDX2 and ELF5 (Figure S1A, B) . Upreg-66 ulation of TBX4 was observed after 6 days. However, overall there were no significant changes 67 in markers associated with neural or mesodermal differentiation after 6 days suggesting that dif-68 ferentiation to these lineages did not occur (Figure S1A, B) . Immunofluorescence analysis at day 69 6 confirmed expression of the pan-trophoblast marker KRT7, and CTB markers P63 and GATA3 70 ( Figure 1B; Figure S1C ). 71
The putative CTB cells obtained at day 6 were investigated for their ability to differentiate 72 to EVTs and STB, using protocols similar to those previously employed (Sarkar et al., 2015) . Cells 73 underwent an epithelial to mesenchymal transition over a 6-day period when passaged into E8 74 medium supplemented with epidermal growth factor (EGF) and SB431542. Immunofluorescence 75 analysis showed expression of KRT7 and the EVT markers VE-Cadherin and HLA-G ( Figure 1C , 76 S1D). Alternatively, passaging CTB-like cells in E6 medium (E8 without TGF1 and bFGF) sup-77 plemented with activin and EGF resulted in formation of KRT7+ multinucleate cells expressing 78 the STB markers hCG and syncytin over an 8-day period (Figure 1D , S1E). Removal of S1P 79 from the medium during hESC differentiation to CTB-like cells abolished formation of EVTs that 80 express HLA-G and VE-Cadherin (Figure 1E, S2A ) under identical differentiation conditions (Fig-81 ure 1A). Differentiation to STB also did not occur in the absence of S1P, as evidenced by lack of 82 expression of syncytin and KRT7 (Figure 1F, S2B) . Also, downregulation of the CTB marker 83 CDX2 and upregulation of transcripts of neural and mesoderm markers was observed in cells 84 after 6 days of differentiation, upon removal of S1P ( Figure S2C) . Taken together these results 85
show that CTB-like cellssimilar to those in previous studies utilizing more complex culture con-86 ditions (Sarkar et al., 2015) can be obtained by differentiation of hESCs in a chemically defined 87 medium containing S1P. Further, inclusion of S1P is necessary for hESC differentiation to troph-88 oblast in our chemically defined culture medium. 89
Rho GTPase signaling, downstream of GPCRs activated by S1P, has been implicated in 90 nuclear localization of YAP (Mo et al., 2012; Ohgushi et al., 2015) . Both Rho/RhoA associated 91 kinase (ROCK) and nuclear YAP play a critical role in trophectoderm specification in the mouse 92 (Kono et al., 2014; Nishioka et al., 2009) . Therefore, we investigated the role of Rho/ROCK sig-93 naling and YAP in trophoblast differentiation of hESCs. The Rho/ROCK inhibitor Y-27632 was 94 included during differentiation of hESCs to CTB-like cells and subsequent differentiation to EVT 95 and STB to investigate the role of Rho/ROCK signaling. Under these conditions, HLA-G expres-96 sion was observed in cells obtained from H9 hESCs; however, VE-Cadherin expression was weak 97 and observed in only a few cells (Figure S2D) . On the other hand, expression of EVT markers 98 was not observed in cells derived from H1 hESCs. Additionally, presence of ROCK inhibition 99 abolished STB formation, as shown by lack of expression of syncytin and KRT7 (Figure S2E) . 100
To investigate the role of YAP signaling in trophoblast differentiation of hESCs, we used 101 an hESC cell line (H9) that expresses an inducible shRNA against YAP (H9-YAP-ishRNA) or a 102 scrambled shRNA control (Hsiao et al., 2016) . YAP knockdown abolished differentiation to EVT 103 and STB, as evidenced by lack of expression of the relevant markers. Notably, high cell death 104 was observed (Figure S2D, E) . Gene expression analysis revealed significant reduction in ELF5 105 upon YAP knockdown, relative to the scrambled shRNA control (Figure S2F ). Significant down-106 regulation of the mesodermal genes TBX4 and LMO2 was observed, whereas T was upregulated, 107 in H9-YAP-ishRNA, relative to the scrambled control. Taken together, these results show that 108
Rho/ROCK signaling, and YAP are necessary for differentiation of hESCs to functional CTB that 109 can give rise to both EVTs and STB, in our chemically defined culture medium. 110 (B) Immunostaining of KRT7, P63 and GATA3 in H9 hESCs at day 6 of initial treatment. Nuclei were stained with DAPI.
(C) Confocal images of EVTs from 12-day treatment of H9 hESCs, staining for KRT7, HLA-G and VE-Cadherin. Nuclei were stained with DAPI.
(D) Confocal images of STB from 14-day treatment of H9 hESCs, staining for KRT7, syncytin and hCG. Nuclei were stained with DAPI.
(E) Confocal images of cells from 12-day EVT treatment of H9 hESCs upon removal of S1P, staining for HLA-G and VE-Cadherin. Nuclei were stained with DAPI.
(F) Confocal images of cells from 14-day STB treatment of H9 hESCs upon removal of S1P staining for KRT7 and syncytin. Nuclei were stained with DAPI.
Scale bars are 100µm for all images. S1P mediates its effects on trophoblast differentiation of hESCs through its receptors. 111 S1P acts through both receptor-mediated and receptor-independent pathways (Maceyka 112 et al., 2012; Mendelson et al., 2014) . To investigate the specific mechanism of S1P action during 113 hESC differentiation to trophoblast, we replaced S1P with D-erythro-dihydrospingosine-1-phos-114 phate (dhS1P) in our protocol. dhS1P acts as an agonist for the S1P receptors (S1PRs) but does 115 not mediate an intracellular effect (Van Brocklyn et al., 1998) . Replacing S1P with dhS1P yielded 116 similar results -CTB-like cells showed high expression levels of CDX2, GATA3, P63, and TEAD4 117 (Figure 2A; Figure S3A ). Upon further differentiation as previously described (Figure 1A) , STB 118 expressing KRT7 and hCG, and EVT expressing HLA-G and VE-Cadherin were obtained ( Figure  119 2B, C; Figure S3B , C). 120 S1P acts extracellularly through S1PR1-5 (Maceyka et al., 2012; Mendelson et al., 2014) , 121 however trophoblasts have been shown to only express S1PR1-3 (Johnstone et al., 2005) . To 122 identify specific S1PRs involved in trophoblast differentiation of hESCs in our culture system, we 123 used selective chemical agonists for S1PR1-3 -CYM5442 hydrochloride, CYM5520 and 124 CYM5541, respectivelyto replace S1P in differentiation protocols previously discussed. Expres-125 sion of CDX2, GATA3, P63, and TEAD4 was observed in CTB-like cells for all three agonists 126 (Figure 2A; Figure S3A ). Similarly, use of each agonist resulted in expression of the EVT mark-127 ers HLA-G and VE-Cadherin, and formation of multinucleate STB expressing KRT7 and hCG 128 ( Figure 2B, C; Figure S3B , C). However, we observed some variability between the agonists. 129
The intensity of CDX2 and P63 expression was higher with S1PR1 agonist CYM5442 and the 130 S1PR3 agonist CYM5541. Nuclear P63 expression was strongest for CYM5442 compared to 131 CYM5541. Notably, use of the S1PR2 agonist CYM5520 resulted in lower expression of CDX2, 132 strong cytoplasmic expression of P63, and high heterogeneity in staining at day 6 relative to the 133 other agonists. Formation of large multinucleated STB was more pronounced when the S1PR2 134 or S1PR3 agonists were used, as compared to the S1PR1 agonist. On the other hand, the S1PR1 135 and S1PR3 agonists enhanced formation of mesenchymal EVTs, relative to the S1PR2 agonist. 136
Taken together, our results show that receptor-mediated effects of exogenous S1P are 137 sufficient for trophoblast differentiation of hESCs in our culture system. Since our qualitative ob-138 servations showed that use of the S1PR3 agonist resulted in high CDX2 expression, and both 139 multinucleate STB and mesenchymal EVTs could be obtained when the S1PR3 agonist was 140 used, we chose the S1PR3 agonist for subsequent studies. 141 Figure 2 : S1P mediates its effects on trophoblast differentiation of hESCs through its receptors.
(A) Confocal images of CTB-like cells from 6-day treatment of H9 hESCs using D-erythro-dihydrospingosine-1-phosphate (dhS1P), CYM5442 (S1PR1 agonist), CYM5220 (S1PR2 agonist), and CYM5541 (S1PR3 agonist), staining for CDX2, GATA3, P63, and TEAD4. Nuclei were stained with DAPI.
(B) Confocal images of STB cells from 14-day treatment of H9 hESCs using dhS1P, CYM5442, CYM5520, and CYM5541 during the initial 6-day treatment, staining for KRT7 and hCG. Nuclei were stained with DAPI.
(C) Confocal images of EVT cells from 12-day treatment of H9 hESCs using dhS1P, CYM5442, CYM5220, and CYM5541 during the initial 6-day treatment, staining for HLA-G and VE-Cadherin. Nuclei were stained with DAPI.
Scale bars are 100µm for all images.
Optimizing timing of hESC differentiation enables derivation of CDX2 + hTESCs. 142
We investigated whether CTB-like cells obtained by treatment of hESCs with BMP4 and 143 SB431542 in E7 medium supplemented with the S1PR3 agonist CYM5541 for 6 days could be 144 passaged and maintained under conditions used for culture of primary hTSCs (Okae et al., 2018) . 145
Upon plating in trophoblast stem cell medium (TSCM) developed by Okae et al. (2018) , hESC-146 derived CTB-like cells underwent differentiation, and epithelial colonies could not be retained after 147 a single passage. CDX2 expression is upregulated significantly in as little as 2 days after initiation 148 of hESC differentiation (Figure S1A, B) . Additionally, previous studies have reported differentia-149 tion of hESCs to CDX2 + /p63 + cells upon treatment with BMP for 4 days (Horii et al., 2016) . There-150 fore, we explored the use of a shorter differentiation step for obtaining CTB-like cells. After 3 days 151 of differentiation, H9 and H1 hESCs expressed nuclear CDX2, P63, and TEAD4 uniformly ( Figure  152 3B). Quantitative image analysis showed that nearly all cells are CDX2+ at day 3, in contrast to 153 CTB-like cells at day 6. Notably, use of a 6-day protocol resulted in significantly reduced fraction 154 CDX2+ cells in the case of H1 hESCs in comparison to H9 hESCs; H9 cells retained CDX2+ cells 155 longer ( Figure 3C) . 156 CDX2+ cells at day 3 were passaged into a chemically defined medium containing four 157 major components (denoted TM4)the S1PR3 agonist CYM5541, the GSK3 inhibitor 158 CHIR99021, the TGF inhibitor A83-01, and FGF10. CHIR99021 and A83-01 are components of 159 TSCM used for culture of primary hTSCs; FGF10 was included because FGFR2b signaling is 160 active in primary hTSCs and the early placenta (Okae et al., 2018) . Cells in TM4 could be main-161 tained as epithelial colonies for 30+ passages over the course of 5 months. In TM4 medium, 162 cells derived from H9 and H1 hESCs expressed the trophoblast markers CDX2, TFAP2C, YAP, 163 TEAD4, and GATA3 (Figure 3D; Figure S4A ) (Choi et al., 2012; Home et al., 2012; Nishioka et 164 al., 2008; Niwa et al., 2005; Ralston et al., 2010; Yagi et al., 2007) . Additionally, cells expressed 165 the pan-trophoblast marker KRT7, and low levels of P63, which is expressed in CTBs found in 166 the placental villi. Notably, CDX2 expression has been strongly associated with the trophecto-167 derm and is lost once placental villi are formed (Blakeley et al., 2015; Hemberger et al., 2010; 168 Horii et al., 2016; Knöfler et al., 2019) . Due to their expression of CDX2, and to distinguish them 169 from trophoblast stem cells that do not express CDX2, these cells are denoted as human 170 trophectoderm stem cells (hTESCs). 171 P63 + hTSCs derived from hESCs can be maintained in TSCM. 172
We evaluated whether hTESCs could be maintained in TSCM used for culturing primary 173 hTSCs ( Figure 3A ) (Okae et al., 2018) . When hTESCs cultured in TM4 for 5+ passages were 174 directly passaged into TSCM, cells underwent a change in colony morphology over ~ 3 passages; 175 however, very little differentiation was observed. Notably, cell morphology of the hESC-derived 176 cells closely resembled that of primary hTSCs in TSCM ( Figure S5A) (Okae et al., 2018) . Strik-177 ingly, however, hESC-derived hTESCs lost expression of CDX2 and gained high expression of 178 P63. As discussed earlier, cells could be maintained as epithelial colonies when hESCs after 3 179 days of differentiation were passaged into TM4. In contrast, passaging day-3 differentiated hESCs 180 into TSCM resulted in extensive differentiation, although a few epithelial colonies could be ob-181 served. Further passaging resulted in similar morphological changes in the epithelial colonies as 182 those observed for hTESCs transitioning to TSCM. After ~ 6 passages, only epithelial colonies 183 remained, and they closely resembled both the hTESCs transitioned into TSCM and primary 184 hTSCs. H9 and H1 hESC-derived cellspassaged directly into TSCM after 3 days of differenti-185 ation or transitioned from TM4 ( Figure 3A) showed high expression of YAP, TEAD4, TFAP2C, 186 and GATA3, similar to cells in TM4, but no expression of CDX2 (Figure 3E; Figure S4B ). Lastly, 187 hESC-derived hTSCs exhibit similar expression profile of trophoblast markers as primary hTSCs 188 ( Figure S5B) . Therefore, these cells are denoted as hTSCs. 189
We further evaluated the differentiation potential of hESC-derived hTSCs using same pro-190 tocols as those used by Okae et al. (2018) for differentiation of primary hTSCs to EVTs and STB 191 (Okae et al., 2018) . Similar to primary hTSCs, the hESC-derived hTSCs could be differentiated 192 into mesenchymal EVTs expressing HLA-G and VE-Cadherin (Figure 3F; Figure S4C ) and mul-193 tinucleate cells expressing the STB markers hCG and KRT7 (Figure 3G; Figure S4D ). Further, 194 hESC-derived hTSCs retained their ability to differentiate into STB-and EVTs after 30 passages 195 in TSCM. Strikingly however, hTESCs did not differentiate to EVTs using the same protocols used 196 for hTSCs ( Figure S5C) . Taken together along with differences in culture conditions for mainte-197 nance and expression of the trophectoderm marker CDX2, these results suggest that hTESCs 198 and hTSCs represent two distinct stem cell populations, with hTESCs being a more primitive cell 199 type. 200 (G) Confocal images of STB from H9 hESC-derived hTSCs staining for hCG and KRT7. Nuclei were stained with DAPI. Scale bars are 100µm.
Transcriptome analysis confirms equivalence of hESC-derived and primary hTSCs and re-201 veals differences between hTSCs and hTESCs 202
We conducted genome wide transcriptome analysis on hTESCs, and hESC-derived and 203 primary hTSCs using RNA sequencing. Principal component analysis (PCA) of transcriptomic 204 signatures showed that hESC-derived and primary hTSCs cluster together, indicating similarities 205 in overall gene expression ( Figure 4A) . Hierarchical clustering analysis further confirmed the very 206 high transcriptome similarity between hESC-derived and primary hTSCs (Figure 4B) . In conjunc-207 tion with similarities in marker expression and culture conditions for maintenance and differentia-208 tion, these results establish the equivalence of hESC-derived and primary hTSCs. 209 PCA also showed that hTESCs are a distinct population of cells that cluster differently 210 from hTSCs and hESCs differentiated to the trophoblast lineage for 3 days (Figure 4A) . Higher 211 expression of the trophectoderm-associated markers CDX2 and HAND1 is observed in hTESCs 212 relative to hTSCs. On the other hand, expression of TP63associated with villous CTBis 213 higher in hTSCs relative to hTESCs (Figure 4C) . Statistical analysis of gene expression profiles 214 identified genes that were significantly differentially expressed between hTESCs and hTSCs. 215
Specifically, 269 genes showed significantly higher expression levels, and 275 genes showed 216 significantly lower expression levels in hTESCs vs. hTSCs (Tables S1 and S2) . Gene set enrich-217 ment analysis of these genes identified 300 and 47 gene ontology (GO) categories (out of 9996 218 queried categories) associated with genes showing higher and lower expression in hTESCs vs 219 hTSCs, respectively (Tables S3 and S4) . Interestingly, consistent with differences in colony mor-220 phology between hTESCs and hTSCs, genes associated with extracellular matrix, biological ad-221 hesion, and cell-cell adhesion were upregulated in hTESCs. Taken together along with distinct 222 medium requirements for maintenance in cell culture, and differences in EVT differentiation under 223 identical assay conditions, these results show that hTSCs and hTESCs represent distinct stem 224 cell populations. 225 (C) Relative expression of trophectoderm-associated markers CDX2 and HAND1 and villous CTB-associated marker TP63 in H1 and H9 hESC-derived hTESCs and hTSCs (*q<0.001).
HTESCs and hTSCs can be generated from hiPSCs. 226
Lastly, we investigated if our results on derivation of hTESCs and hTSCs from hESCs can 227 be extended to hiPSCs. Accordingly, we used our previously described protocols (Figure 3A) to 228 derive hTESCs and hTSCs from the hiPSC line SBli006-A. HTESCs derived from SBli006-A hiP-229
SCs maintained expression of CDX2, TFAP2C, GATA3, YAP KRT7, and TEAD4, along with low 230 expression level of P63 in TM4 (Figure 5A) . Similarly, hTSCs derived from SBli006-A hiPSCs 231 expressed KRT7, P63, TEAD4, TFAP2C, YAP, and GATA3 in TSCM (Figure 5B) . Similar to the 232 case with hESC-derived hTSCs, cells lost expression of CDX2 but gained higher expression lev-233 els of P63 and KRT7 in TSCM. Differentiation of hTSCs derived from SBli006-A hiPSCs using 234 protocols described by Okae et al. (2018) , resulted in formation of mesenchymal EVTs with high 235 expression of HLA-G and VE-Cadherin (Figure 5C) , and multinucleate STB expressing hCG and 236 KRT7 (Figure 5D) . These results show that hTESCs and hTSCs can also be derived from hiP-237 SCs. 238 
Discussion 239
In this study, we have shown that two distinct stem cell populations of the trophectoderm lineage 240 -hTSCs and hTESCscan be derived from hESCs and hiPSCs under chemically defined culture 241 conditions. Whether bona fide trophoblast can be obtained from human pluripotent stem cells 242 has been a subject of debate (Roberts et al., 2014) . Despite extensive research in this area, 243 conducting a rigorous head-to-head comparison between hESC-derived and primary trophoblasts 244 has been challenging. The isolation of trophoblast stem cell populations from hESCs in this study, 245 in conjunction with the recent derivation of primary hTSCs (Okae et al., 2018) enabled such a 246 comparison. We have shown that hESCs can be differentiated to hTSCs that express markers 247 consistent with primary hTSCs (P63, TEAD4, TFAP2C, YAP, and GATA3). The hESC-derived 248 hTSCs are cultured in the same medium as primary hTSCs and differentiate to EVT and STB 249 using similar protocols as those used for primary hTSCs. Further, hESC-derived hTSCs and pri-250 mary hTSCs have highly similar transcriptomes. Taken together, these results establish the equiv-251 alence of hESC-derived and primary hTSCs and demonstrate that hESCs can indeed differentiate 252 to bona fide trophoblasts. 253
Role of receptor mediated S1P signaling and hESC culture medium in trophoblast differ-254 entiation of hESCs. 255
Previous studies on trophoblast differentiation of hESCs have employed differing protocols, re-256 sulting in significantly different outcomes in some cases. Notably, Bernardo et al. (2011) reported 257 that BMP treatment of hESCs results in differentiation of hESCs to mesoderm and not trophoblast. 258
Our studies suggest two potential explanations for discrepancies in previous studies. First, our 259 results show that receptor-mediated signaling by the albumin-associated sphingolipid S1P plays 260 a critical role in hESC differentiation to trophoblast in our medium. Differences in results reported 261 by previous studies may be due to variability in the lipid composition of media used during troph-262 oblast differentiation of hESCs. Second, the medium used for routine maintenance of undifferen-263 tiated hESCs likely contributes significantly to their differentiation potential. For instance, unlike 264 hESCs cultured in the presence of KSR, hESCs in E8 medium exhibit features of naïve pluripo-265 tency (Cornacchia et al., 2019) . Recent studies report the conversion of hESCs to expanded po-266 tential stem cells (EPSCs) by transitioning hESCs to a human EPSC medium. Significantly, hTSC-267 like cells can be obtained by passaging EPSCsbut not hESCs in KSR containing mediumin 268 TSCM used for culture of primary hTSCs (Gao et al., 2019) . The efficiency of establishing hTSC-269 like lines was low (~ 30% with manual isolation of colonies) and a rigorous transcriptome com-270 parison with primary hTSCs was not conducted. Nevertheless, taken together these studies un-271 derscore the importance of hESC culture conditions in their differentiation potential. Differences 272 in culture conditions for undifferentiated hESCs may lead to inconsistent results during trophoblast 273 differentiation of hESCs. 274
Our results show that Rho/ROCK signaling and YAP are necessary for trophoblast differ-275 entiation of hESCs in our medium. However, the exact molecular mechanisms that underlie ac-276 quisition of trophoblast fate in the presence of S1P receptor activation need to be further studied. 277
Our results do not preclude the possibility that Rho/ROCK and/or YAP acts independently of S1P 278 receptor mediated signaling in our system. 279
Differences between hTESCs and hTSCs 280
Marker expression analysis, functional differentiation assays, and genome-wide transcriptome 281 analysis confirm the equivalence of hESC-derived hTSCs and primary hTSCs that are similar to 282 villous CTB. However, hTESCs differ significantly from hTSCs. They do not undergo differentia-283 tion to EVTs under the culture conditions used for differentiating hESC-derived and primary 284 hTSCs. Transcriptome analysis shows that genes associated with several key pathways and bi-285 ological processes are differentially regulated between hTESCs and hTSCs. Significantly, 286 hTESCsbut not hTSCsexpress high levels of the trophectoderm-associated markers CDX2 287 and HAND1. Therefore we opt for the nomenclature human trophectoderm stem cells (hTESCs) 288 as proposed by Knöfler et al. (2019) , to distinguish these CDX2+ stem cells from hTSCs. Con-289 sistent with the more primitive nature of hTESCs, they can be readily transitioned into TSCM used 290 for culturing hTSCs, as was seen by Okae et al. (2018) when transitioning trophectoderm cells of 291 blastocysts into TSCM. Subsequently, similar to primary hTSCs, hTESCs lose expression of 292 CDX2 and express higher levels of P63 in TSCM, and can differentiate to form EVTs and STB. 293
Note that primary hTSCs derived from the trophectoderm in the blastocyst stage embryo lose 294 expression of CDX2 in TSCM (Okae et al., 2018) . On the other hand, it has not been possible yet 295 to revert hTSCs to hTESCs by culturing in TM4 medium. Further studies are needed to rule out 296 the possibility of such a reversion to the more primitive cell type. 297
Considerations for derivation and culture of hTESCs 298
To derive hTESCs, undifferentiated hESCs maintained in E8 medium are first treated for 3 days 299 with the S1PR3 agonist, BMP4 and the activin/nodal inhibitor SB4315432, to obtain CDX2+ cells. 300
Subsequently, CDX2+ cells are passaged in TM4 medium to obtain hTESCs. Using this protocol, 301
we observed increased differentiation of H1-derived cells upon passage into TM4 medium, rela-302 tive to H9-and SBli006-A-derived cells. Shortening the initial treatment step in case of H1 hESCs 303 to 2 days eliminated excessive differentiation and facilitated derivation of hTESCs. However, we 304 were unable to derive hTESCs with any cell line when the initial treatment was greater than 3 305
days. 306
In our studies, the initial hESC differentiation step was carried out in E7 medium that con-307 tains bFGF. Differentiation of hESCs to trophoblast has been carried out in the presence or ab-308 sence of exogenous FGF (Amita et al., 2013; Das et al., 2007) . Consistent with this, we found 309 that hTESCs could be formed even if the initial treatment was carried out in E6 medium lacking 310 bFGF, instead of E7 medium. 311
It is important to note that hTESCs proliferate slower in culture than hTSCs. We also ob-312 serve that the attachment of hTESCs to tissue culture plates is less efficient than hTSCs. Finally, 313
we observe that excessive differentiation in TM4 medium during early passages could be coun-314 tered by reducing the concentration of ascorbic acid (32 g/mL instead of 64 g/mL) in TM4. 315
Additional studies on composition of TM4 medium or the substrates used to coat tissue culture 316 plates may lead to improved growth rate and attachment efficiency. Alternatively, the slower 317 growth rate and less efficient attachment characteristics may be an inherent feature of the hTESC 318 state. Nonetheless, we have successfully maintained hTESCs derived from all cell lines studied 319 for at least 20 passages, in several independent runs over 5+ months. We recommend passaging 320 hTESCs routinely at higher cell densities relative to hTSCs, and troubleshooting cell line specific 321 variability by optimizing the initial treatment step and/or lowering ascorbic acid concentration in 322 TM4. 323
Derivation of hTSCs from hiPSCs 324
We have shown that hTESCs and hTSCs can be derived from hiPSCs. Since hiPSCs can 325 be derived by reprogramming easily accessible somatic tissues, hTSCs and hTESCs derived 326 from hiPSCs can greatly accelerate research in placental biology. Further, arguably a limitation 327 of primary hTSCs is that pregnancy outcomes at term for the early gestation placental samples 328 or blastocyst stage embryos used cannot be predicted accurately. In contrast, hiPSC-derived 329 hTSCs and hTESCs, from hiPSCs generated using somatic tissues obtained at term, will enable 330 development of models of validated normal and pathological trophoblast development. Perti-331 nently, Sheridan et al. (2019) have derived hiPSCs from umbilical cords of normal pregnancies 332 and those associated with early onset preeclampsia. Our results also gain particular significance 333 in the light of restrictions on research with fetal tissue (Du Toit, 2019) . 334
In conclusion, using optimized cell culture protocols detailed in the current study, we have 335 derived two distinct stem cell populations of the trophectoderm lineage -hTESCs and hTSCs -336 from human pluripotent stem cells. These stem cell models will be powerful tools for in vitro 337 studies on human trophoblast development. 338
Anti-CDX2
Abcam Cat# ab76541, RRID:AB_1523334 Culture of hESCs and hiPSCs 341 H1 and H9 hESCs and SBli006-A hiPSCs were cultured on plates coated with vitronectin (5 µg/ml) 342 at room temperature for at least one hour. Cells were cultured in 2 ml of TeSR-E8 medium at 343 37°C in 5% CO 2 in 6-well plates and culture medium was replaced every day. When cells reached 344 confluency, they were passaged using ReLeSR according to the manufacturer's protocol, at a 345 1:10 split ratio. 346 
Differentiation of hESCs (6 days protocol) 347
The day after passaging, differentiation was initiated in H1 or H9 hESCs by treatment with S1P 348 (10 µM), SB431542 (25 µM) and BMP4 (20 ng/ml) in TeSR-E7 for 6 days. In some experiments, 349 the S1PR agonists CYM5442 hydrochloride (10 nM), CYM5520 (5 µM), CYM5541 (2 µM), or the 350 Rho/ROCK inhibitor Y-27632 (5 µM), or doxycycline (2 µM), and/or puromycin (1.5 µg/mL) was 351 added during the differentiation process. The medium was replaced every day. At day 6 of treat-352 ment, cells were dissociated with TrypLE for 5 min at 37°C. For differentiation to EVTs, cells were 353 seeded in a 6-well plate pre-coated with 5 µg/ml of vitronectin at a density of 7×10 4 cells per well 354 and cultured in 2 ml of TeSR-E8 medium supplemented with SB431542 (25µM) and EGF (2.5 355 ng/ml). Medium was replaced every other day and analyzed at day 12 of total treatment. For 356 differentiation to STB, cells were seeded in a 6-well plate pre-coated with 5 µg/ml of vitronectin at 357 a density of 4×10 4 cells per well and cultured in 2 ml of TeSR-E6 supplemented with Activin A (20 358 ng/ml) and EGF (50 ng/ml). Medium was replaced every other day and analyzed at day 14 of 359 total treatment. 360
To investigate the role of YAP signaling in TB formation from hESCs, we used an hESC 361 cell line (H9) that expresses an inducible shRNA against YAP (H9-YAP-ishRNA) (Hsiao et al., 362 2016) . This cell line along with a scrambled shRNA control were a kind gift from Dr. Sean Palecek 363 (University of Wisconsin). shRNA expression was induced with doxycycline under constant ex-364 posure to puromycin as the selection marker. 365
Differentiation of hESCs to hTESCs and hTSCs 366
The day after passaging, hESCs were differentiated by treatment with CYM5541 (2 µM), 367 SB431542 (25 µM), BMP4 (20 ng/ml) in TeSR-E7 for 2 and 3 days for H1 and H9 hESCs, respec-368 tively. The medium was replaced every day. After 2 or 3 days of treatment, cells were dissociated 369
with TrypLE for 5 minutes at 37°C. For propagation of hTESCs, all cells were seeded in a 6-well 370 plate pre-coated with 3 µg/ml of vitronectin and 1 µg/ml of Laminin 521 at a density of ~5×10 4 371 cells per well and cultured in 2 ml of TM4 medium [TeSR-E6 medium supplemented with 372 CYM5541 (2 µM), A 83-01 (0.5 µM), FGF10 (25ng/ml) and CHIR99021 (2 µM)]. For establish-373 ment of hTSCs, all cells were seeded in a 6-well plate pre-coated with 3 µg/ml of vitronectin and 374 1 µg/ml of Laminin 521 at a density of ~5×10 4 cells per well and cultured in 2 ml of TSCM devel-375 oped by Okae et al. (2018) [DMEM/F12 supplemented with 0.1 mM 2-mercaptoethanol, 0.2% 376 FBS, 0.5% Penicillin-Streptomycin, 0.3% BSA, 1% ITS-X supplement, 1.5 µg/ml L-ascorbic acid, 377 50 ng/ml EGF, 2 µM CHIR99021, 0.5 µM A83-01, 1 µM SB431542, 0.8 mM VPA and 5 µM 378 Y27632]. HTESCs were directly passaged into TSCM for formation of hTSCs; complete transition 379 took ~ 5 passages. Alternatively, hESC after 2 or 3 days of differentiation were directly passaged 380 into TSCM. 381
Culture of hTESCs and hTSCs 382
HTESCs and hTSCs were cultured in TM4 and TSCM, respectively, in 2 ml of culture medium at 383 37C in 5% CO 2 . Culture medium was replaced every 2 days. When hTESCs or hTSCs reached 384 70-90% confluence, they were dissociated with TrypLE at 37°C for 5-10 minutes and passaged 385 to a new 6-well plate pre-coated with 3 µg/ml of vitronectin and 1 µg/ml of Laminin 521 at a 1:3-386 1:4 split ratio for hTESCs and 1:4-1:6 split ratio for hTSCs. hTESCs grown in TM4 medium were 387 supplemented with Y-27632 upon passage to aid in single cell attachment. Cells were routinely 388 passaged approximately every 4-6 days. hTESCs and hTSCs at passages 5+ were used for 389 analysis, with the exception of one replicate of H1-derived hTESCs used in RNA-sequencing 390 analysis where cells at passage 2 in TM4 were used. 391 CT29 and CT30 primary hTSCs were a kind gift from Dr. Hiroaki Okae (Tohoku University, 392 Japan (Okae et al., 2018) ). Primary hTSCs were cultured in TSCM, similar to hESC-derived 393 hTSCs. 394
Differentiation of hTESCs and hTSCs 395
hTSCs were grown to ~80-90% confluence in TSCM and dissociated with TrypLE for 10 min at 396 37°C. For differentiation to EVTs and STB, slightly modified versions of protocols developed by 397 Okae et al. (2018) were used. For differentiation to EVTs, hTSCs were seeded in 6-well plates 398 pre-coated with 3 µg/ml vitronectin and 1 µg/ml of Laminin 521 at a density of 1.25×10 5 cells per 399 well and cultured in 2 mL of EVT medium (DMEM/F12 supplemented with 0.1 mM 2-mercaptoeth-400 anol, 0.5% Penicillin-Streptomycin, 0.3% BSA, 1% ITS-X supplement, 100 ng/ml NRG1, 7.5 µM 401 A83-01, 2.5 µM Y27632, and 4% KSR). Matrigel was added to a final media concentration of 2% 402 after suspending the cells in EVT medium. At day 3, the medium was replaced with the EVT 403 medium without NRG1, and Matrigel was added to a final concentration of 0.5%. At day 6, cells 404
were dissociated with TrypLE for 15 min at 37°C and passaged to a new vitronectin/laminin-405 coated 6-well plates at a 1:2 split ratio. The cells were suspended in the EVT medium without 406 NRG1 and KSR. Matrigel was added to a final concentration of 0.5%, and cells were analyzed 407 after two additional days of culturing. For differentiation to STB, cells were seeded in 6-well plates 408 pre-coated 3 µg/ml vitronectin and 1 µg/ml of Laminin 521 at a density of 1.5×10 5 cells per well 409 and cultured in 2 mL of DMEM/F12 supplemented with 0.1 mM 2-mercaptoethanol, 0.5% Penicil-410 lin-Streptomycin, 0.3% BSA, 1% ITS-X supplement, 2.5 µM Y27632, 2 µM forskolin, and 4% KSR. 411
The medium was replaced at day 3, and cells were analyzed at day 6. 412
RNA Isolation, cDNA synthesis and Quantitative PCR. 413
RNA was isolated using Trizol TM reagent using the manufacturer's protocol. For cDNA synthesis, 414 the RNA pellet was dissolved in diethyl pyrocarbonate (DEPC)-treated water. The RNA was pu-415 rified using Baseline-ZERO DNase buffer and Baseline-ZERO DNase enzyme and incubating at 416 37°C for 30 min. The purification was stopped with Baseline-ZERO DNase stop solution and 417 heated at 65°C for 10 min. cDNA was synthesized using 18-mer Oligo-dT and dNTP mix and 418 heated to 65°C for 5 min and quickly chilled on ice. First strand buffer and DTT was added and 419 incubated at 42°C for 2 min then superscript II RT enzyme was added and incubated at 42°C for 420 50 min. The enzyme was inactivated at 70°C for 15 min. The cDNA was stored at -20°C until 421 further used. The Quantitative PCR (qPCR) reaction was carried out using SYBR Green Super-422 mix in a C1000 Touch Thermal Cycler CFX384 Real-Time System (Rio-Rad). The primers used 423 for qPCR analysis are listed in Methods S1. ANOVA analysis of gene expression data was 424 carried out with SAS software using the ΔΔCt method to determine gene expression changes 425 (Livak and Schmittgen, 2001) . QPCR analysis was carryout out using three biological replicates 426 for H9 and H1 hESCs as specified in the figure panels. 427
Immunofluorescence analysis 428
For immunofluorescence analysis, cells were grown on glass-bottom culture dishes coated with 429 3 µg/ml vitronectin and 1 µg/ml of Laminin 521. Cells were fixed either using 4% paraformalde-430 hyde in PBS for 10 min, permeabilized with 0.5% Triton X-100 for 5 min and blocked in 3% 431 BSA/PBS with 0.1% human IgG and 0.3% Triton X-100 for 1 hr. Cells were then incubated over-432 night with the primary antibody diluted in blocking buffer. The following primary antibodies were 433 used: anti-KRT7 (SCB, 1:50), anti-KRT7 (CST, 1:500), rabbit anti-hCG (1:100), mouse anti-hCG 434
(1:100), anti-YAP (1:200), anti-TFAP2C (1:400), anti-P63 (1:600), anti-GATA3 (1:500), anti-435 TEAD4 (1:250), anti-CDX2 (1:300), anti-VE-Cadherin (1:400), anti-HLA-G (1:300), anti-syncytin 436
(1:50). Corresponding isotype controls (rabbit polyclonal IgG, rabbit XP IgG, mouse IgG1, and 437 mouse IgG2a) were used at primary antibody concentrations. Alexa Fluor 488-or Alexa Fluor 438 647-conjugated secondary antibodies were used as secondary antibodies. Nuclei were stained 439 with DAPI and all samples were imaged using a Zeiss LSM 710 or 880 laser scanning confocal 440 microscope (Carl Zeiss, Germany). 441
Confocal image analysis 442
Image analysis was conducted using an image processing algorithm created in MATLAB. First, 443 the DAPI stain was isolated, binarized, and processed to accurately represent the number of cells 444 in each image. The primary-antibody stain of interest was isolated and processed in the same 445 manner. Only primary-antibody pixels that overlap DAPI pixels were considered for analysis, and 446 the average intensities of those pixels were measured and correlated to the nearest nuclei. This 447 was performed for one control image and multiple experimental images. Each cell in the experi-448 mental images was considered positively stained if the average intensity of that cell was greater 449 than the average intensity of all of the cells in the control image. Statistical analysis was done 450 using a two-tailed t-test evaluating percent positive cells from different treatment periods. 451
RNA sequencing analysis using next generation sequencing 452
Total RNA was extracted with Trizol TM reagent using manufacturer's protocol. RNA was purified 453 using GeneJET RNA Purification Kit using manufacturer's protocol. Isolated RNA samples were 454 then used to evaluate genome-wide mRNA expression profiles using next generation RNA-se-455 quencing, conducted at GENEWIZ, LLC. (South Plainfield, NJ, USA). RNA samples received at 456 GENEWIZ were quantified using Qubit 2.0 Fluorometer (Life Technologies, Carlsbad, CA, USA) 457 and RNA integrity was checked using Agilent TapeStation 4200 (Agilent Technologies, Palo Alto, 458 CA, USA). 459 RNA sequencing libraries were prepared using the NEBNext Ultra RNA Library Prep Kit 460 for Illumina following manufacturer's instructions (NEB, Ipswich, MA, USA). Briefly, mRNAs were 461 first enriched with Oligo(dT) beads. Enriched mRNAs were fragmented for 15 minutes at 94 °C. 462
First strand and second strand cDNAs were subsequently synthesized. cDNA fragments were 463 end repaired and adenylated at 3'ends, and universal adapters were ligated to cDNA fragments, 464
followed by index addition and library enrichment by limited-cycle PCR. The sequencing libraries 465 were validated on the Agilent TapeStation (Agilent Technologies, Palo Alto, CA, USA), and quan-466 tified by using Qubit 2.0 Fluorometer (Invitrogen, Carlsbad, CA) as well as by quantitative PCR 467 (KAPA Biosystems, Wilmington, MA, USA). 468
The sequencing libraries were clustered on 4 lanes of a flowcell. After clustering, the 469 flowcell was loaded on the Illumina HiSeq 4000 instrument according to manufacturer's instruc-470 tions. The samples were sequenced using a 2x150bp Paired End (PE) configuration. Image 471 analysis and base calling were conducted by the HiSeq Control Software (HCS). Raw sequence 472 data (.bcl files) generated from Illumina HiSeq was converted into fastq files and de-multiplexed 473 using Illumina's bcl2fastq 2.17 software. One mismatch was allowed for index sequence identifi-474
cation. 475
After investigating the quality of the raw data, sequence reads were trimmed to remove 476 possible adapter sequences and nucleotides with poor quality using Trimmomatic v.0.36. The 477 trimmed reads were mapped to the Homo sapiens GRCh38 reference genome available on EN-478 SEMBL using the STAR aligner v.2.5.2b. The STAR aligner is a splice aligner that detects splice 479 junctions and incorporates them to help align the entire read sequences. BAM files were gener-480 ated as a result of this step. Unique gene hit counts were calculated by using feature Counts from 481 the Subread package v.1.5.2. Only unique reads that fell within exon regions were counted. 482
Analysis of gene expression profiles 483
After extraction of gene hit counts, the gene hit counts table was used for downstream differential 484 expression analysis. Genome-wide RNA sequencing count data were processed and statistically 485 assessed using the DESeq2 package (v1.22.2) in R Software (3.6.0) (The R Foundation, 2019). 486
Count data were first filtered to include transcripts expressed above background, requiring the 487 median across samples to be greater than the overall median signal intensity, as implemented in 488
DESeq2. Count data were then normalized by median signal intensity using algorithms enabled 489
